Brain natriuretic peptide and the risk of cardiovascular events in hemodialysis patients
Abstract
The aim of the study was to determine the prognostic role of brain natriuretic peptide (BNP) in development of adverse cardiovascular events in patients on program hemodialysis. We studied BNP level and performed ultrasonography in 51 patients with CRF on hemodialysis. Adverse cardiovascular events developed in 14 (27,45%) patients for one year of followup. A significant correlation was found between BNP concentration and systolic and diastolic myocardial function. BNP level was significantly above (p < 0,01) in patients with adverse cardiovascular events compared to patients without them. An increase in quartile BNP was accompanied by an increase in frequency of the end final point (р < 0,05). The relative risk of development of a final point in 4th quartile in comparison with 1st quartile, has made 3,23 (95% ДИ [1,59; 11,8]; р < 0,05). Conclusions: the BNP level is significantly increased in patients on hemodialysis compared to practically healthy people. There is a statistically significant correlation between the BNP concentration and structure and functional myocardial indexes. BNP level was increased in those hemodialysis patients who had adverse cardiovascular events. The raised level BNP is prognostic a marker of adverse cardiovascular outcomes at patients, being on treatment by a program hemodialysis.
About the Authors
O. E. Ilyicheva
The Chelyabinsk state medical academy of Federal agency on public health services and social development
Russian Federation
Russian Federation
U. V. Kharlamova
The Chelyabinsk state medical academy of Federal agency on public health services and social development
Russian Federation
Russian Federation
N. N. Nezdojmina
The Chelyabinsk state medical academy of Federal agency on public health services and social development
Russian Federation
Russian Federation
References
1. Агеев Ф.Т., Овчинников А.Г. Мозговой натрийуретический гормон и дисфункция левого желудочка // Сердечная недостаточность. 2009. Т. 10. № 5. С. 271–281.
2. Бикбов Б.Т., Томилина Н.А. О состоянии заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2003 гг.: отчет по данным регистра Российского диализного общества // Нефрология и диализ. 2005. Т. 7. № 3. С. 204–275.
3. Bay M., Kirk V., Parner J. et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function // Heart. 2003. Vol. 89. P. 150–154.
4. Bibbins-Domingo K., Gupta R., Na B. et al. N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease // JAMA. 2007. Vol. 297. P. 169–176.
5. Clerico A., Iervasi G., Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide honnones in hymans // Horm. Metab. Res. 1999. Vol. 31. № 9. Р. 487–489.
6. De Lemos J.A., Morrow D.A., Bentley J.H. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes // N Engl J Med. 2001. Vol. 345. P. 1014–1021.
7. Dokainish H., Zoghbi W.A., Lakkis N.M. et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure // Am. Coll. Cardiol. 2005. Vol. 45. № 8. P. 1223–1226.
8. Kasap S., Gönenç A., Şener D.E., Hisar İ. Serum Cardiac Markers in Patients with Acute Myocardial Infarction: Oxidative Stress, C-Reactive Protein and N-Terminal Probrain Natriuretic Peptide // J Clin Biochem Nutr. 2007. Vol. 41. № 1. P. 50–57.
9. Latini R., Masson S., Wong M. et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure // Am J Med. 2006. Vol. 119. № 1. P. 3–30.
10. Levey S.A., Eknoyan G. Cardiovascular disease in chronic renal disease // Nephrol. Dial. Transplant. 1999. Vol. 14. P. 828–833.
11. Tsutamoto T., Wada A., Maeda K. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure // Circulation. 1997. Vol. 96. P. 509–516.
12. Vanderheyden M., Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects // Eur. J. Ytart. Failure. 2004. Vol. 6. P. 261–268.
13. Wang T.J., Larson M.G., Levy D. Plasma natriuretic peptide levels and the risk of cardiovascular events and death // N Engl J Med. 2004. Vol. 110. № 13. P. 1780–1786.
14. Yoshimura M., Yasue H, Okumura M. et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure // Circulation. 1993. Vol. 87. P. 464–469.
Review
For citations:
Ilyicheva O.E., Kharlamova U.V., Nezdojmina N.N. Brain natriuretic peptide and the risk of cardiovascular events in hemodialysis patients. Nephrology and Dialysis. 2010;12(4):262-264. (In Russ.)
Views:
10
Email this article 